HPC
NAVB

HM Payson & Co’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

HM Payson & Co’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-300
Closed -$1K – 1196
2020
Q3 		$1K Hold
300
– – ﹤0.01% 1033
2020
Q2 		$1K Buy
+300
New +$574 ﹤0.01% 857

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

HM Payson & Co's NAVB Position: Q4 2020 in Review

HM Payson & Co sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2020, closing a stake of 300 shares — an estimated $1K sold.

HM Payson & Co first reported a position in NAVB in Q2 2020 and held it in 2 quarters. The position peaked at $1K in Q3 2020. 36 funds tracked by Wall St. Rank hold NAVB as of Q4 2020.

  • HM Payson & Co reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2020 after selling out during the quarter.
  • HM Payson & Co sold 300 Navidea Biopharmaceuticals Inc. shares in Q4 2020, an estimated $1K.
  • HM Payson & Co first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2020 and held it in 2 quarters.
  • HM Payson & Co's Navidea Biopharmaceuticals Inc. position peaked at $1K in Q3 2020.
  • 36 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2020.

Based on HM Payson & Co's 13F filing for Q4 2020, filed 10 Mar 2021.